Edition:
United Kingdom

People: Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

5.97EUR
1:31pm BST
Change (% chg)

€0.06 (+1.02%)
Prev Close
€5.91
Open
€6.02
Day's High
€6.04
Day's Low
€5.93
Volume
12,999
Avg. Vol
82,574
52-wk High
€9.18
52-wk Low
€4.92

Abert-Engels, Christophe 

Dr. Christophe Abert-Engels is Executive Vice President - Clinical Development & Medical Affairs at Poxel SA. He has more than 25 years of experience in life sciences, academia and industry. Dr. Arbet-Engels’ leadership at several large pharmaceutical companies encompasses clinical development and registration, launch and lifecycle management for several innovative drugs for the treatment of diabetes, metabolism and cardiovascular diseases, including Lantus® (insulin glargine) and Jardiance® (empagliflozin). Most recently, he was Vice President, Worldwide Medical, Collaborative Medical Sciences at Biogen, driving strategy and execution of Phase 3b/4 life cycle management activities. Prior to Biogen, Dr. Arbet-Engels worked in senior leadership positions in clinical development and medical affairs at pharmaceutical and biotech companies, including Boehringer Ingelheim, Roche, Merck, Aventis (now Sanofi) and Ligand Pharmaceuticals. In addition, Dr. Arbet-Engels served as a Medical Advisor to MedNest, provided expertise to the Gerson Lehrman Group, and worked as French Foreign Trade Advisor for the French Government to advise and support French or other startup companies develop their business in the U.S. Dr. Arbet-Engels has a medical degree from University of Paris Sud, a PhD in endocrinology/diabetes and metabolism from Paris Descartes University and a master’s degree in business administration from Rutgers University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --